Logo image of TARO

TARO PHARMACEUTICAL INDUS (TARO) Stock Price, Quote, News and Overview

NYSE:TARO - New York Stock Exchange, Inc. - IL0010827181 - Common Stock - Currency: USD

42.97  0 (0%)

After market: 42.97 0 (0%)

TARO Quote, Performance and Key Statistics

TARO PHARMACEUTICAL INDUS

NYSE:TARO (6/21/2024, 8:26:37 PM)

After market: 42.97 0 (0%)

42.97

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High45.76
52 Week Low32.67
Market Cap1.61B
Shares37.58M
Float8.09M
Yearly Dividend0
Dividend YieldN/A
PE24.98
Fwd PEN/A
Earnings (Next)07-24 2024-07-24/amc
IPO01-01 1961-01-01


TARO short term performance overview.The bars show the price performance of TARO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0.5 1 1.5 2

TARO long term performance overview.The bars show the price performance of TARO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30 -40

The current stock price of TARO is 42.97 USD. In the past month the price increased by 0.44%. In the past year, price increased by 10.83%.

TARO PHARMACEUTICAL INDUS / TARO Daily stock chart

TARO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.44 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.58 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.78 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About TARO

Company Profile

TARO logo image Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Company Info

TARO PHARMACEUTICAL INDUS

14 Hakitor Street, PO Box 10347

Haifa 10532 IL

CEO: Uday Baldota

Employees: 1554

Company Website: https://www.taro.com/

Phone: 97248475700

TARO PHARMACEUTICAL INDUS / TARO FAQ

What is the stock price of TARO PHARMACEUTICAL INDUS today?

The current stock price of TARO is 42.97 USD.


What is the ticker symbol for TARO PHARMACEUTICAL INDUS stock?

The exchange symbol of TARO PHARMACEUTICAL INDUS is TARO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is TARO stock listed?

TARO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for TARO PHARMACEUTICAL INDUS stock?

6 analysts have analysed TARO and the average price target is 43.86 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 42.97. Check the TARO PHARMACEUTICAL INDUS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TARO PHARMACEUTICAL INDUS worth?

TARO PHARMACEUTICAL INDUS (TARO) has a market capitalization of 1.61B USD. This makes TARO a Small Cap stock.


How many employees does TARO PHARMACEUTICAL INDUS have?

TARO PHARMACEUTICAL INDUS (TARO) currently has 1554 employees.


What are the support and resistance levels for TARO PHARMACEUTICAL INDUS (TARO) stock?

TARO PHARMACEUTICAL INDUS (TARO) has a support level at 42.8 and a resistance level at 43.11. Check the full technical report for a detailed analysis of TARO support and resistance levels.


Should I buy TARO PHARMACEUTICAL INDUS (TARO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TARO PHARMACEUTICAL INDUS (TARO) stock pay dividends?

TARO does not pay a dividend.


When does TARO PHARMACEUTICAL INDUS (TARO) report earnings?

TARO PHARMACEUTICAL INDUS (TARO) will report earnings on 2024-07-24, after the market close.


What is the Price/Earnings (PE) ratio of TARO PHARMACEUTICAL INDUS (TARO)?

The PE ratio for TARO PHARMACEUTICAL INDUS (TARO) is 24.98. This is based on the reported non-GAAP earnings per share of 1.72 and the current share price of 42.97 USD. Check the full fundamental report for a full analysis of the valuation metrics for TARO.


TARO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to TARO. When comparing the yearly performance of all stocks, TARO turns out to be only a medium performer in the overall market: it outperformed 68.84% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TARO Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to TARO. TARO has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TARO Financial Highlights

Over the last trailing twelve months TARO reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 156.72% compared to the year before.


Industry RankSector Rank
PM (TTM) 8.55%
ROA 2.49%
ROE 3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%122.22%
Sales Q2Q%12.52%
EPS 1Y (TTM)156.72%
Revenue 1Y (TTM)9.81%

TARO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to TARO. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners1.69%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts43.33
Price Target43.86 (2.07%)
EPS Next YN/A
Revenue Next YearN/A